Biomea Fusion Presents New Clinical and Translational Data for Icovamenib at the American Diabetes Association (ADA) 86th Scientific Sessions and Announces Expansion of Ongoing Phase I BMF-650 Study
•Translational data presented at ADA demonstrate icovamenib’s potential to promote muscle preservation…
Biomea Fusion Presents Phase II COVALENT-111 Data in Type 2 Diabetes at the 19th International Conference on Advanced Technologies & Treatments for Diabetes 2026
SAN CARLOS, Calif., March 14, 2026 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc.…
Biomea Fusion to Participate in Citi’s SMID Biotech C-Suite Fireside Chat Series
October 21, 2025 19:05 ET | Source: Biomea Fusion, Inc. SAN CARLOS,…
